【参】六角形画像(Vision)
H1

Our Goal

コンテンツ

Top Message

We are pleased to make a new start as Kidswell Bio Corporation, or KWB, from July 1, 2021. As Gene Techno Science Co., Ltd., or GTS, we successfully established a basis of our solid and stable growth in the biosimilar business. With such success, we are striving for further growth by exploring the new biologics and regenerative medicine business.
KWB will challenge a new field, pediatric disease, in addition to intractable and rare diseases on which GTS has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children’s potential vital force such as SHED and CSC, we envision creating new pharmaceuticals and therapeutics for all people.
Under “Kids Well, All Well”, we will make our goal come true!

July, 2021

 Kidswell Bio Corporation
President & CEO
Masaharu Tani



01

Masaharu Tani
President & CEO

The Univ. of Tokyo, MSc, MBA
Joined the Clinical Development Dept. at Suntory, implementing clinical trials and moved to Takeda Pharmaceutical, where worked at the Business Development Dept. and Strategic Product Planning Dept. After Takeda, joined Whiz Partners, a Japanese investment company in 2013 and joined GTS in 2014. Appointed as CFO in 2015 and CEO in 2017 at GTS.

02

Masayuki Kawakami
Corporate Officer, CTO, Research & Development Div.

Kyoto Univ. Graduate School of Engineering, Ph.D
Worked for research laboratories of FUJIFILM Corp. mainly in oncology area with Harvard Univ. and Novartis (then Sandoz). Worked for Toyama Chemical Corp. and then for FUJIFILM Pharmaceuticals USA to promote an anti-influenza drug clinical development. Joined GTS in April 2017 and appointed as CTO in April 2018.

03

Shinya Kurebayashi
Corporate Officer, CBO, Business Development Div.

Massachusetts Institute of Technology, MSc, Physics
Worked in Investment Banking Div. at Goldman Sachs Japan and involved in M&A, IPOs and bond offerings of pharmaceutical and medical device companies at Morgan Stanley (Mitsubishi UFJ Morgan Stanley Securities). A member of launching ImPACT of Cabinet Office. In 2015, joined Advanced Cell Technology And Engineering LTD (ACTE) and established Administration Dept. and led business development and IPO preparation at ACTE. Joined GTS in March 2019.

04

Yasuo Sakae
Corporate Officer, CFO, Business Administration Div.

Bachelor of Faculty of Sociology, Hitotsubashi Univ.
Sales & Marketing at Commerz Securities(affiliate of Commerzbank)Tokyo Branch and HQ in Germany and then joined in Yamanouchi/ Astellas, worked mainly for globalization of finance function including establishment of Corporate Venture Capital. CFO at Astellas US, VP, Procurement, VP, Corporate Finance & Control at Astellas Pharma, Japan and VP, Corporate Strategy & Communications at Astellas Europe. Joined GTS in April 2018.

コンテンツ

KIDS WELL, ALL WELL

KIDS WELL, ALL WELL

Aiming at providing comprehensive healthcare solutions for patients as well as families and caregivers


Start-up, IPO, Business Expansion

From Now On

For the Future

For the Future

Connecting advanced biotehcnologies existing in Japan,
and contributing to the brighter future for chirdren

Business Direction

Targeting diseases which has less accessibility for sufficient medical treatment, and exploring the new therapeutic area

Target Area

Pediatric disease (Including juvenile one), Orphan disease, Intractable disease, Asia-endemic disease

Our Mission

By applying the sophisticated biotechnologies

By applying the sophisticated biotechnologies, developing
credible products and services are essential for KWB to contribute to society across the world.

Brighter future for children

Declining birthrate and the aging population becomes a social
issue all over the world. It is no doubt that children and young people will be the generation to create next society. Important thing is for those young people to be able to live healthier and higher quality of life. Brighter future for children with our biotechnoloigies